CytomX醫療 CTMX 深 滬
等待開盤 09-02 09:30:00 美东时间
2.04
-0.010
-0.49%
華盛通- 最 高2.07
- 今 開2.07
- 成交量 121.56万股
- 最 低 1.99
- 昨 收 2.05
- 總市值 3.37亿
- 52周最高 3.095
- 市盈率 靜 5.42
- 換手率 0.74%
- 52周最低 0.40
- 委 比 6.17%
- 總股本 1.65亿
- 歷史最高 35.00
- 量 比 0.47
- 振 幅 3.90%
- 歷史最低 0.40
- 每 手 1
- 風險率 0.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CytomX Therapeutics to Present at Upcoming September Investor Conferences
<p align="justify">CytomX Therapeutics announced that its management will participate in three investor conferences in September 2025: the Cantor Global Healthcare Conference, H.C. Wainwright 27th Annual Global Investment Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference, all held in New York City. Additionally, live webcasts of their presentations will be available on CytomX’s website, www.cytomx.com. The company focuses on...
08-28 12:00
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
08-22 16:35
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
Celldex Therapeutics报告了其针对嗜酸性食管炎（EoE）的二期临床试验顶线结果。研究显示，其候选药物barzolvolimab显著减少了胃肠道中的肥大细胞，但并未改善临床症状，表明肥大细胞可能并非EoE的主要驱动因素。药物安全性良好。 Celldex将不会推进barzolvolimab在EoE中的开发，但将继续探索其在其他适应症中的潜力。公司将于今日举办网络研讨会讨论结果。
08-19 20:01
美股机会日报丨贝森特称九月或降息50个基点；中国资产爆发！网易盘前涨超5%，阿里巴巴盘前涨超3%
贝森特称九月或降息50个基点；中国资产爆发！网易盘前涨超5%，阿里巴巴盘前涨超3%；马斯克：特斯拉Robotaxi9月将向公众开放>>
08-13 21:03
期权扫描 | Meta创新高！期权成交激增172%；BBAI看涨期权涌入占比近63%
Meta创新高！期权成交激增172%至60万张；BBAI绩后重挫，看涨期权涌入占比近63%>>
08-13 14:02
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
CytomX Therapeutics has enrolled 73 colorectal cancer patients in their CTMX-2051-101 Phase 1 study, aiming to provide a data update in Q1 2026. The study remains active with patients continuing to receive CX-2051 across all expansion doses. A single Grade 5 treatment-related acute kidney injury occurred in a patient with a complex medical history, reported to the FDA. The Safety Review Committee supported continued study execution. CX-2051 is a ...
08-13 12:00
CytomX Therapeutics Q2 Sales $18.658M Beat $14.725M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly sales of $18.658 million which beat the analyst consensus estimate of $14.725 million by 26.71 percent. This is a 25.71 percent decrease over sales of $25.115 million
08-08 04:13
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
CytomX Therapeutics announced positive interim data for CX-2051 in advanced colorectal cancer and planned dose expansions. CX-801 combination therapy with KEYTRUDA for melanoma is progressing. The company completed a $100 million stock offering, ended Q2 2025 with $158.1 million in cash, and reported reduced operating expenses. CX-2051 Phase 1 data update is expected in Q1 2026, with potential Phase 2 initiation in 1H 2026. Multiple research coll...
08-07 20:10
